0000899243-20-004907.txt : 20200218 0000899243-20-004907.hdr.sgml : 20200218 20200218165916 ACCESSION NUMBER: 0000899243-20-004907 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200214 FILED AS OF DATE: 20200218 DATE AS OF CHANGE: 20200218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 20626139 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-14 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1600 CHICAGO IL 60601 0 1 0 0 See Remarks Common Stock 2020-02-14 4 P 0 2410 4.15 A 6115 D Represents shares purchased in an underwritten public offering of the Issuer at the public offering price of $4.15 per share. Senior Vice President, Clinical Development, Regulatory, Quality Assurance and Medical Affairs /s/ Beth Hecht, as Attorney-in-Fact 2020-02-18